Halozyme Therapeutics (HALO) Cash from Financing Activities (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Cash from Financing Activities data on file, last reported at -$1.6 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 51.43% year-over-year to -$1.6 million in Q1 2026; TTM through Mar 2026 was -$83.5 million, a 62.35% increase from a year earlier, with the FY2025 full-year figure at -$85.2 million, up 61.08% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$1.6 million, down from $239.5 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for HALO reached as high as $367.8 million in Q2 2022 and fell as low as -$299.0 million in Q2 2025.
• Historically, Cash from Financing Activities has averaged -$20.7 million across 5 years, with a median of -$489000.0 in 2024.
• Across the five-year window, Cash from Financing Activities surged 921.81% in 2022 and tumbled 26480.45% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at $6.3 million in 2022, then plunged by 4048.81% to -$249.9 million in 2023, then increased by 1.4% to -$246.4 million in 2024, then soared by 197.2% to $239.5 million in 2025, then tumbled by 100.67% to -$1.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$1.6 million in Q1 2026, $239.5 million in Q4 2025, and -$22.4 million in Q3 2025.